BCMA Bispecifics in Myeloma: Do Real-World Results Match Clinical Trials? | IMS 2026

Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center, University of Miami discusses real-world data on BCMA bispecific antibodies at IMS 2026 in Glasgow. He shares a review of 12 real-world studies showing results similar to the trials that led to approval, with fewer infections reported in some data. He explains why infections happen and how care teams prevent them, the shift toward outpatient step-up dosing, and how bispecifics are being studied in newly diagnosed and high-risk smoldering myeloma.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.